Hosted on MSN4d
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same PageShares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
the most surprising aspect of the earnings release was that Regeneron declared a dividend for the first time in its history, of $0.88 per quarter, which translates to an annual yield of ~0.53% - a ...
Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback